MDA-MB-231-Luc
Strain Information
Validation Data
The MDA-MB-231-Luc cell line is an MDA-MB-231 mammary carcinoma cell line with stable and high expression of Luciferase.
· The subcutaneous tumorigenesis test showed this cell line could form tumors normally in M-NSG mice. Luciferase activity was showed a steady increase in tumor bearing mouse models.
· MDA-MB-231-Luc cells were injected into M-NSG mice via intra-femoral artery. The fluorescence signal of Luciferase increased steadily in vivo.
· In M-NSG mice, orthotopic tumors formed in mammary fat pads and it was found that metastasis could mainly occur in the liver after excision of the orthotopic tumors.
· After internal-carotid artery injection into M-NSG and Balb/C nude mice, brain metastases could form and the Luciferase fluorescence signal in brain increased significantly.
Figure 1. Morphology of MDA-MB-231-Luc cell line.
Figure 2. Luciferase activity assay of MDA-MB-231-Luc cell line.
Figure 3. (A) Average growth curves of MDA-MB-231-Luc tumors. (B) Body weights of MDA-MB-231-Luc tumor bearing mice. (C) Survival curves of MDA-MB-231-Luc xenograft mouse models. (n=9)
MDA-MB-231-Luc cells were subcutaneously injected into M-NSG mice.
Figure 4. In vivo luciferase activity curves of MDA-MB-231-Luc xenograft mouse models (A: supine position, B: prone position). (n=4~5)
MDA-MB-231-Luc cells were injected into M-NSG mice via intra-femoral artery.
Figure 5. Body weights (A) and survival curves (B) of MDA-MB-231-Luc xenograft mouse models. (n=4~5)
MDA-MB-231-Luc cells were injected into M-NSG mice via intra-femoral artery.
Figure 6. In vivo bioluminescence imaging of MDA-MB-231-Luc xenograft mouse models.
MDA-MB-231-Luc cells were injected into M-NSG mice via intra-femoral artery injection.
Figure 7. Average growth curves of MDA-MB-231-Luc orthotopic tumors in mammary fat pads. (n=5)
MDA-MB-231-Luc cells were inoculated into mammary fat pads of M-NSG mice.
Figure 8. In vivo luciferase activity curves of MDA-MB-231-Luc orthotopic tumors in mammary fat pads. (n=5)
Figure 9. In vivo bioluminescence imaging of MDA-MB-231-Luc xenograft mouse models bearing orthotopic tumors in mammary fat pads.
Figure 10. Survival curves of MDA-MB-231-Luc xenograft mouse models. (n=5)
Figure 11. In vivo luciferase activity curves of MDA-MB-231-Luc xenograft mouse models after orthotopic tumors in mammary fat pads were removed. (n=3-4)
Figure 12. In vivo bioluminescence imaging of MDA-MB-231-Luc xenograft mouse models after orthotopic tumors in mammary fat pads were removed.
Luciferase activity curves showed an increase during the formation of hepatic metastases.
Figure 13. In vivo luciferase activity curves of brains in MDA-MB-231-Luc xenograft mouse models.
MDA-MB-231-Luc cells were injected into M-NSG mice (n=3) (A) and Balb/c nude mice (n=5) (B) via internal-carotid artery.
Figure 14. Survival curves of MDA-MB-231-Luc xenograft mouse models.
MDA-MB-231-Luc cells were injected into M-NSG mice (n=3) (A) and Balb/C nude mice (n=5) (B) via internal-carotid artery.
Figure 15. In vivo bioluminescence imaging of brains in MDA-MB-231-Luc xenograft mouse models. MDA-MB-231-Luc cells were injected into M-NSG mice (A) and Balb/C nude mice (B) via internal-carotid artery.
You may also like
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreAt GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more